+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia-Pacific Veterinary Vaccine Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4771833
  • Report
  • February 2019
  • Region: Asia Pacific
  • 76 pages
  • Mordor Intelligence
UP TO OFF
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Ceva Sante Animale
  • Eli Lilly & Company
  • Hester Biosciences Ltd
  • HIPRA
  • Merck & Co.
  • Virbac SA
  • MORE
Market Overview

The Asia-Pacific veterinary vaccine market is expected to witness a CAGR of 6.12% over the forecast period. The key factors propelling the growth of this market are the increasing incidences of livestock diseases, initiatives by various government agencies, animal associations, leading players in the Asia-Pacific region, and the increasing incidences of zoonotic diseases.

According to the National Dairy Development Board 2017, India has a cattle population of 158.7 million and it has one of the largest animal husbandry sectors in the world, along with the largest livestock population, with 520.6 million heads. Furthermore, in 2016, Zoetis and Merial entered into an agreement for marketing and distribution drugs and vaccines for dairy cattle in India. Merial is expected to market and sell Zoetis products, including brands, such as Bovical, Rispoval, Spirovac, and many others. Thus, increasing cattle population in the region and increasing prevalence of diseases, along with improved distribution reach, with vaccine institutes reaching smaller districts, are some of the factors that are augmenting the growth of the market.

Scope of the Report

The Asia-Pacific veterinary vaccine market has been segmented based on vaccine type, technology, and geography. By vaccine type, the market is divided into livestock vaccines and companion animal vaccines. By technology, the market is divided into live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and other technologies.

Key Market Trends

The Live Attenuated Vaccines Segment is Expected to Hold the Largest Market Share

The live attenuated vaccines segment of the Asia-Pacific veterinary vaccine market is believed to have the largest market size, and it is expected to witness a CAGR of approximately 5.12% during the forecast period.

All vaccines licensed for oral or intranasal administration are attenuated. These vaccines must be stored and handled properly, with strict attention to temperature, even in the lyophilized (free-dried) state. After the reconstitution, the vaccine dose should be administered promptly (within 1 hour) or discarded. Some examples of these types of vaccines include canine distemper virus vaccines and all canine parvovirus and adenovirus-2 vaccines. As of 2018, these vaccines had the largest market share among others, and it is expected to record a CAGR of 5.12% during the forecast period.

Competitive Landscape

The Asia-Pacific veterinary vaccine market is a moderately consolidated market and consists of several major players. In terms of market share, a few of the major players currently dominate the market. Companies, like Zoetis Inc., Merck & Co. Inc., Virbac, Eli Lily and Company, and Boehringer Ingelheim International GmbH, hold the substantial market share in the Asia-Pacific veterinary vaccine market.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ceva Sante Animale
  • Eli Lilly & Company
  • Hester Biosciences Ltd
  • HIPRA
  • Merck & Co.
  • Virbac SA
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidences of Livestock Diseases
4.2.2 Initiatives by Various Government Agencies, Animal Associations, and Leading Players
4.2.3 Increasing Incidences of Zoonotic Diseases
4.3 Market Restraints
4.3.1 High Storage Costs for Vaccines
4.3.2 Lack of Veterinarians and Shortage of Skilled Farms
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Animal Vaccine Type
5.1.1 Livestock Vaccines
5.1.1.1 Bovine Vaccines
5.1.1.2 Poultry Vaccines
5.1.1.3 Porcine Vaccines
5.1.1.4 Other Livestock Vaccines
5.1.2 Companion Animal Vaccines
5.1.2.1 Canine Vaccines
5.1.2.2 Feline Vaccines
5.1.2.3 Equine Vaccines
5.2 By Technology
5.2.1 Live Attenuated Vaccines
5.2.2 Inactivated Vaccines
5.2.3 Toxoid Vaccines
5.2.4 Recombinant Vaccines
5.2.5 Other Technologies
5.3 Geography
5.3.1 Asia-Pacific
5.3.1.1 China
5.3.1.2 Japan
5.3.1.3 India
5.3.1.4 Australia
5.3.1.5 South Korea
5.3.1.6 Rest of Asia-Pacific

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Zoetis Inc.
6.1.2 Merck & Co.
6.1.3 Virbac SA
6.1.4 Hester Biosciences Ltd
6.1.5 Eli Lilly & Company
6.1.6 Boehringer Ingelheim International GmbH
6.1.7 Ceva Sante Animale
6.1.8 Phibro Animal Health Corp.
6.1.9 HIPRA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Zoetis Inc.
  • Merck & Co.
  • Virbac SA
  • Hester Biosciences Ltd
  • Eli Lilly & Company
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Phibro Animal Health Corp.
  • HIPRA
Note: Product cover images may vary from those shown
Adroll
adroll